Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world.
  • Posted by Pei Li Teh
  • August 22, 2019
  • Videos

Conducting research for publication

Pei Li Teh explains how real world insights provide an opportunity for brands to find, demonstrate and communicate their value to patients, healthcare and society.
 

read more »

  • Posted by Pei Li Teh
  • May 30, 2018
  • Events

Eyeforpharma Real World Evidence Conference Round up 2018

Earlier this month, APAC Director Pei Li Teh attended Asia’s 11th Eyeforpharma conference in Tokyo, Japan with a focus on Real World Evidence (RWE)

This year has seen a turning point for Japan's pharma industry, as the government and the industry encourage a rapid move towards increased use of RWE from April 2018. Real World Data (RWD) sources provide an unprecedented opportunity for companies to find, demonstrate and communicate their real value to patients, healthcare and society. The conference included topics addressing commercial and medical needs, allowing both communities to come together for the first time encouraging collaboration across functions.

read more »

  • Posted by Pei Li Teh
  • April 19, 2018
  • Events

Eyeforpharma – Real World Evidence 2018

Eyeforpharma – Real World Evidence 2018

16-17 May in Tokyo, Japan

Research Partnership is delighted to be attending the Eyeforpharma Real World Evidence (RWE) conference in Tokyo, Japan 16-17 May. RWE is currently a very hot topic for the Japanese pharma industry, with an increased push to place RWE as a strategic imperative for pharma.

read more »

  • Posted by Rachel Howard
  • February 15, 2017
  • Articles

Cool heads in a crisis?

Cool heads in a crisis?

Understanding the role pharmaceutical companies can play in fighting today’s global health pandemics

First there was Ebola and now there is Zika; two official World Health Organization (WHO) Public Health Emergencies of International Concern (PHEIC) within as many years.  Whenever global health crises such as these emerge, the pharmaceutical industry comes under intense scrutiny for not having an immediate solution available. Part of the problem is that prevention is not always financially viable; the substantial R&D costs of developing vaccines or treatments for all known and potential threats that may or may not one day develop into global pandemics is not a feasible burden for the industry to carry alone. 

read more »